Literature DB >> 15365799

Clinical effects of flurbiprofen tooth patch on radiation-induced oral mucositis. A pilot study.

M A Stokman1, F K L Spijkervet, F R Burlage, J L N Roodenburg.   

Abstract

BACKGROUND: Mucositis is an oral sequela of radiotherapy. In the development of mucositis several mechanisms play a role, such as inflammation and the effect of radiation on the high proliferation rate of oral basal epithelial cells. Therefore, administration of a drug with antiinflammatory and antiproliferative properties might delay the disorder and/or alleviate the severity of oral mucositis. The aim of this pilot study was to evaluate the effect of flurbiprofen in a tooth patch on the development, severity and duration of pseudomembranous mucositis in patients treated with curative head and neck radiotherapy.
METHODS: The study group comprised 12 patients with a malignant tumor in the head and neck region to be treated with primary curative or postoperative radiotherapy. Patients applied once a day before sleep a flurbiprofen tooth patch to a natural tooth or upper denture during the full course of radiotherapy, starting 1 week before the onset of radiotherapy. Oral mucositis, pain, feeding, body weight and viability and maturation of epithelial cells were assessed. The results were compared with the findings in a historical control group.
RESULTS: No differences were found for severity and duration of pseudomembranous mucositis between the two groups. The onset of pseudomembranous/ulcerative mucositis occurred later in the flurbiprofen group (14.6+/-3.8 days, mean+/-SD) than in the historical control group (11+/-3.5 days; P<0.05).
CONCLUSION: This study shows that the flurbiprofen 15 mg tooth patch cannot prevent the development of pseudomembranous mucositis and has no influence on the duration of oral mucositis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15365799     DOI: 10.1007/s00520-004-0674-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  24 in total

1.  Quantification of oral mucositis due to radiotherapy by determining viability and maturation of epithelial cells.

Authors:  M A Stokman; F K L Spijkervet; A N M Wymenga; F R Burlage; W Timens; J L N Roodenburg; E G E de Vries
Journal:  J Oral Pathol Med       Date:  2002-03       Impact factor: 4.253

2.  The radiobiological basis for tissue reactions in the oral cavity following therapeutic x-irradiation. A review.

Authors:  D G Baker
Journal:  Arch Otolaryngol       Date:  1982-01

Review 3.  Cyclooxygenase in biology and disease.

Authors:  R N Dubois; S B Abramson; L Crofford; R A Gupta; L S Simon; L B Van De Putte; P E Lipsky
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

4.  Sucralfate for radiation mucositis: results of a double-blind randomized trial.

Authors:  R Meredith; M Salter; R Kim; S Spencer; B Weppelmann; B Rodu; J Smith; J Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

5.  Povidone-iodine to prevent mucositis in patients during antineoplastic radiochemotherapy.

Authors:  R Rahn; I A Adamietz; H D Boettcher; V Schaefer; K Reimer; W Fleischer
Journal:  Dermatology       Date:  1997       Impact factor: 5.366

6.  The influence of field size and other radiotherapy parameters on acute toxicity in pharyngolaryngeal cancers.

Authors:  R Miralbell; A S Allal; B Mermillod; B Pastoors
Journal:  Strahlenther Onkol       Date:  1999-02       Impact factor: 3.621

7.  Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis.

Authors:  Edward B Rubenstein; Douglas E Peterson; Mark Schubert; Dorothy Keefe; Deborah McGuire; Joel Epstein; Linda S Elting; Philip C Fox; Catherine Cooksley; Stephen T Sonis
Journal:  Cancer       Date:  2004-05-01       Impact factor: 6.860

Review 8.  Mucositis incidence, severity and associated outcomes in patients with head and neck cancer receiving radiotherapy with or without chemotherapy: a systematic literature review.

Authors:  Andy Trotti; Lisa A Bellm; Joel B Epstein; Diana Frame; Henry J Fuchs; Clement K Gwede; Eugene Komaroff; Luba Nalysnyk; Marya D Zilberberg
Journal:  Radiother Oncol       Date:  2003-03       Impact factor: 6.280

9.  Scoring irradiation mucositis in head and neck cancer patients.

Authors:  F K Spijkervet; H K van Saene; A K Panders; A Vermey; D M Mehta
Journal:  J Oral Pathol Med       Date:  1989-03       Impact factor: 4.253

Review 10.  Prevention and treatment of the consequences of head and neck radiotherapy.

Authors:  A Vissink; F R Burlage; F K L Spijkervet; J Jansma; R P Coppes
Journal:  Crit Rev Oral Biol Med       Date:  2003
View more
  6 in total

1.  Randomized double-blind placebo-controlled trial of celecoxib for oral mucositis in patients receiving radiation therapy for head and neck cancer.

Authors:  Rajesh V Lalla; Linda E Choquette; Kathleen F Curley; Robert J Dowsett; Richard S Feinn; Upendra P Hegde; Carol C Pilbeam; Andrew L Salner; Stephen T Sonis; Douglas E Peterson
Journal:  Oral Oncol       Date:  2014-08-21       Impact factor: 5.337

Review 2.  Anti-inflammatory agents in the management of alimentary mucositis.

Authors:  Rajesh V Lalla; Mark M Schubert; Rene-Jean Bensadoun; Dorothy Keefe
Journal:  Support Care Cancer       Date:  2006-03-25       Impact factor: 3.603

Review 3.  Nuclear and Radiological Emergencies: Biological Effects, Countermeasures and Biodosimetry.

Authors:  Elena Obrador; Rosario Salvador-Palmer; Juan I Villaescusa; Eduardo Gallego; Blanca Pellicer; José M Estrela; Alegría Montoro
Journal:  Antioxidants (Basel)       Date:  2022-05-31

Review 4.  Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients.

Authors:  Ourania Nicolatou-Galitis; Triantafyllia Sarri; Joanne Bowen; Mario Di Palma; Vassilios E Kouloulias; Pasquale Niscola; Dorothea Riesenbeck; Monique Stokman; Wim Tissing; Eric Yeoh; Sharon Elad; Rajesh V Lalla
Journal:  Support Care Cancer       Date:  2013-05-24       Impact factor: 3.603

5.  Text mining-based in silico drug discovery in oral mucositis caused by high-dose cancer therapy.

Authors:  Jon Kirk; Nirav Shah; Braxton Noll; Craig B Stevens; Marshall Lawler; Farah B Mougeot; Jean-Luc C Mougeot
Journal:  Support Care Cancer       Date:  2018-02-23       Impact factor: 3.603

Review 6.  Development of Antioxidant COX-2 Inhibitors as Radioprotective Agents for Radiation Therapy-A Hypothesis-Driven Review.

Authors:  Markus Laube; Torsten Kniess; Jens Pietzsch
Journal:  Antioxidants (Basel)       Date:  2016-04-19
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.